Tibra Equities Europe’s Immunic IMUX Stock Holding History

Tibra Equities Europe’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-153	Closed	-$416K	–	153
2018 Q1	$416K	Buy	+153	New	+$351K	0.07%	136

Other funds holding IMUX

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tibra Equities Europe's IMUX Position: Q2 2018 in Review

Tibra Equities Europe sold out of Immunic (IMUX) in Q2 2018, closing a stake of 153 shares — an estimated $416K sold.

Tibra Equities Europe first reported a position in IMUX in Q1 2018 and held it in 1 quarter. The position peaked at $416K in Q1 2018. 62 funds tracked by Wall St. Rank hold IMUX as of Q2 2018.

Tibra Equities Europe reported no remaining Immunic position as of Q2 2018 after selling out during the quarter.
Tibra Equities Europe sold 153 Immunic shares in Q2 2018, an estimated $416K.
Tibra Equities Europe first reported a position in Immunic in Q1 2018 and held it in 1 quarter.
Tibra Equities Europe's Immunic position peaked at $416K in Q1 2018.
62 funds tracked by Wall St. Rank held Immunic as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.